DVA DaVita Inc.
USHealthcareAs of 2026-07-10 16:00
Why DVA matters now
DaVita Inc. (DVA) is a US stock in Healthcare. The latest InvestLog snapshot shows $232.80 with +1.45% on the session and $14.94B in market capitalization; recent performance reads 1-month +6.83% and YTD +83.00%.
The latest financial table shown here is Q1 2026, with revenue of $3.42B, net income of $197.5M, and EPS of $2.87. Investors can compare that operating picture with valuation signals such as P/E 13.43 and FCF yield 11.2%.
The latest indexable market news headline is "DaVita HealthCare (DVA) Laps the Stock Market: Here's Why" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $199.50; recent insider activity includes Rodriguez Javier filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
13.43
PEG
—
P/B
-18.55
P/S
0.96
EV/EBITDA
9.57
DCF Value
$232.40
FCF Yield
11.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
31.1%
Operating Margin
15.0%
Net Margin
5.6%
ROE
-133.1%
ROA
4.5%
ROIC
10.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.42B | $197.5M | $2.87 |
| Q4 2025 | $3.62B | $234.2M | $2.45 |
| FY 2025 | $13.64B | $746.8M | $9.51 |
| Q3 2025 | $3.42B | $150.3M | $2.04 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$202.25
Target (Median)
$199.50
Target Range
$190.00 - $220.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Care Facilities
Country
US
Exchange
—
Beta
0.91
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.